Developer of small molecule kinase inhibitors that target vascular leakage (edema), vascular proliferation (angiogenesis), and inflammation. The company offers its products for the treatment of human diseases, such as heart attack, cancer, and eye diseases; vascular leakage, edema, and the unwanted growth of new blood vessels; pleural effusions, arthritis, pulmonary edema, transplant ischemia, ARDS, brain inflammation, hypovolemia (acute blood loss) CNS disorders, and other serious medical conditions.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
5. Merger/Acquisition | 21-Jul-2010 | $201M | 00000 | 00000 | Completed | Clinical Trials - Phase 1 |
4. Later Stage VC (Series D) | 12-Jul-2007 | 000.00 | 00000 | 00000 | Completed | Clinical Trials - Phase 1 |
3. Later Stage VC (Series C) | 31-Aug-2005 | 0000 | 000.00 | 00000 | Completed | Generating Revenue |
2. Early Stage VC (Series B) | 13-Jan-2004 | $30.6M | $40.6M | 000.00 | Completed | Generating Revenue |
1. Early Stage VC (Series A) | 03-Apr-2002 | $10M | $10M | 0000 | Completed | Product Development |
Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series D | 00,000,000 | 00.000000 | 00.0 | 00.0 | 00.0 | 00 | 00.0 | 00.000 |
Series C | 00,000,000 | 00.000000 | 00.0 | 00.0 | 00.0 | 00 | 00.0 | 000 |
Series B | 27,061,947 | $0.000100 | $0.09 | $1.13 | $1.13 | 1x | $1.13 | 22.55% |
Series A | 10,000,000 | $0.000100 | $0.08 | $1 | $1 | 1x | $1 | 8.33% |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
BB Biotech Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
CDIB Capital Group | Venture Capital | Minority | 000 0000 | 000000 0 | |
CTI Life Sciences Fund | Venture Capital | Minority | 000 0000 | 000000 0 | |
Chicago Growth Partners | PE/Buyout | Minority | 000 0000 | 000000 0 | |
Enterprise Partners Venture Capital | Venture Capital | Minority | 000 0000 | 000000 0 |